MedPath

ADIAL PHARMACEUTICALS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$6.3M
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms

Phase 3
Completed
Conditions
Alcohol Use Disorder
Interventions
Drug: AD04 (ondansetron)
Drug: Matching placebo
Device: Companion Diagnostic for Genetic Testing
Behavioral: Brief Psychological Counseling
First Posted Date
2019-09-24
Last Posted Date
2024-04-17
Lead Sponsor
Adial Pharmaceuticals
Target Recruit Count
302
Registration Number
NCT04101227
Locations
🇧🇬

Mental Health Centre Prof. Dr. Ivan Temkov Burgas EOOD Department for treatment of Emergency Psychiatric conditions, Burgas, Bulgaria

🇧🇬

State Psychiatric Hospital, Kardzhali, Bulgaria

🇧🇬

UMHAT Dr. Georgi Stranski Second Psychiatric Clinic, Pleven, Bulgaria

and more 21 locations

News

Adial Pharmaceuticals Receives Milestone Payment as Adovate Launches Phase 1 Trial for Novel Asthma Therapy

Adial Pharmaceuticals has received a six-figure milestone payment from Adovate following the initiation of a Phase 1 clinical trial for ADO-5030, a novel adenosine receptor antagonist targeting asthma.

Adial Pharmaceuticals' AD04 Shows Positive Pharmacokinetics for Alcohol Use Disorder Treatment

Adial Pharmaceuticals' AD04 demonstrated predictable bioavailability and dose proportionality in a recent pharmacokinetics study, AD04-103.

© Copyright 2025. All Rights Reserved by MedPath